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Available online 6 December 2016Background: Vitamin K-antagonists such as warfarin treatment remain themainstay to prevent thromboembolic
events in various conditions. The quality of the treatment is reflected through time in therapeutic (INR) range
(TTR) with a threshold at ≥70% indicating ‘good quality’; achieving this quality is not trivial. We conducted a
randomised controlled trial to assess the impact of decision aiding model on treatment quality in a high quality
vitamin K-antagonist treatment setting.
Methods: We investigated if algorithm-suggested warfarin dosing was superior to standard dosing in a high-
quality setting involving self-managing warfarin patients. Patients were initially allocated to either algorithm-
suggestedwarfarin dosing or to standard care treatment, and were crossed over after threemonths. The trial pe-
riod was a total of six months, and the primary endpoint was TTR; we also investigated a secondary endpoint of
log-transformed INR variability.
Results: A total of 191 patients contributed to the main analysis with a mean follow-up time of 140 days; 75%
were males and the mean age was 65 years old. The intervention arm achieved a TTR of 81.6, while the placebo
arm attained a TTR of 80.9 (difference [intervention arm minus placebo arm]: 0.67 (95% confidence interval
−2.93 to 4.27). The difference in INR variability was 0.30 (0.14 to 0.47), favouring the placebo arm in terms of
lower log transformed variability.
Conclusions: We found no difference between the two trial-arms in a high-quality warfarin treatment setup.
However in general, the model performed similarly as to routine patient self-management care. (ClinicalTrials.
gov number: NCT02705976)
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Anticoagulants
Clinical decision support systems
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Therapeutic drug monitoring1. Introduction
Oral anticoagulant (OAC) treatment is effective in preventing throm-
boembolic events in patients at an increased risk such as atrial fibrilla-
tion [1]. However, the drawbacks of treatment with vitamin K-
antagonists (VKA) involve drug-food interaction and International Nor-
malised Ratio (INR) monitoring. Alternative treatment options (often
referred to as non-vitamin K antagonists oral anticoagulants) are now
available, i.e. direct Xa inhibitors or factor II inhibitor [2]. Nevertheless,
VKA treatment remains the mainstay to prevent thromboembolic
events in various conditions e.g. mechanical heart valve replacement,
atrial fibrillation, and secondary prevention of venous thromboembo-
lisms (VTE). Additionally, end-stage renal disease is a contraindicationhUnit, Sønder Skovvej 15, 9000
. This is an open access article underfor use of direct Xa inhibitors or factor II inhibitor due to clearance
pathways.
The quality of VKA treatment is often reflected through time in ther-
apeutic (INR) range (TTR) with a threshold at ≥70% indicating ‘good
quality’ [3]. In a well-managed Swedish cohort of VKA treated patients
with various indications for treatment, the event rates of thromboem-
bolism and major bleeding were around 2%/year [4]. Obtaining a high
quality VKA treatment is not trivial. The highest quality is found when
patients are assigned to patient self-management (PSM) or patient
self-testing [5]. The lowest quality is found in conventional manage-
ment performed by the general practitioner or a hospital department,
and intermediary quality is found in a highly specialized anticoagulation
centre [6–9]. Computerized dosing algorithms for warfarin has been de-
veloped to maintain warfarin dose, and also to aid in the initial dosing
phase [10–13]. However, only few dosing algorithms have been tested
in randomised clinical trials and not in high quality settings reflected
through high TTR levels [14,15].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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rin maintenance dosage, which was demonstrated to be safe in a retro-
spective setting [13,16]. The main advantage of this developedmodel is
use of patient specific parameters, which allow for personalized dosing
suggestions. However, the model has not yet been tested in a prospec-
tive study design. Therefore, we conducted a randomised controlled
trial to assess the impact of the model on treatment quality in a high
quality VKA treatment setting.
2. Methods
2.1. Trial design
The trial was a pragmatic, single-blinded, cross-over, randomised,
controlled trial designed to investigate if algorithm-suggested warfarin
dosing was superior to standard dosing in a high-quality setting involv-
ing PSM patients in warfarin treatment. The study was approved by the
hospital department and the protocol was approved by the National
Ethics Committee [ref. N-20140036]. The trial was conducted in accor-
dancewith the principles of theHelsinki Declaration. The head of centre
and chief physician (TBL) was in charge of clinical safetymatters during
the trial period. Data were collected by the investigators (PBN andMM)
and analysed by a statistician (SLC).
Patients were initially allocated to either algorithm-suggested war-
farin dosing (intervention arm) or to standard care treatment (placebo
arm). After duration of three months, the involved participants were
crossed-over to the other study arm for an additional three months,
see Fig. 1. The cross-over design was chosen to reduce between-
patient variation and with the intention of reducing potential learning
bias, as participantswere introduced to a new computerized dosing sys-
tem (see Trial Procedure description).
The primary study outcome measure was TTR evaluated after six
months comparing intervention versus placebo. A secondary study
measure was the log-transformed INR variability calculated according
to Fihn's method [17]. This method attempts to describe the degree to
which each individual's INR value varies relative to his/hers previous
INR value. Lower (negative) values correspond to more stable INR
variability.
2.2. Trial participants
From September 2014 to November 2014 we enrolled study partic-
ipants at a single centre in Aalborg, Denmark. Eligible participants were
patients with an indication for warfarin treatment who were in steady-
state PSM treatment at the Aalborg Thrombosis Centre, Department of
Cardiology, Aalborg University Hospital. The patient training has been
described previously [18]. In short, patients were educated in monitor-
ing the INR values and to adjust the warfarin treatment accordingly to
achieve a designated target INR range. Participants were required toFig. 1. Trial procedure after randomisation. After three months duration, patients are
crossed to opposite trial arm relative to initial randomisation.be compliant with the online system used at the department
(CoaguCheck Link, Roche Diagnostics, Switzerland); hence eligible par-
ticipants were deemed comfortable in using IT-systems for reporting on
INR values as well as warfarin treatment adherence. Patients with se-
vere co-morbidity, pregnancy, and patients who lacked the ability to
handle the interface on theweb-based system used in the trial were ex-
cluded; see Supplemental Table 1 for detailed inclusion and exclusion
criteria. All patients used the portable coagulometer CoaguChek,
CoaguChek S or the CoaguChek XS (Roche Diagnostics, Switzerland)
equipped with CoaguChek PT-test strips. Inclusion occurred only after
a face-to-face meeting with a study investigator (MM); during this
meeting the patients were introduced to the (new) online system
used in the trial. All patients gave written informed consent before tak-
ing part in the trial.2.3. Trial procedure
Enrolled participants were block randomised, in a 1:1 ratio
consisting of 20 participants in each block, to (initially) either receive
algorithm-suggested warfarin dosing or standard treatment. We
intended to analyse data from a total of 200 patients. Patients declining
to participate after the meeting with a study investigator were still
assigned to the specific block randomisation; hence more than ten
randomisation blocks (20 participants × 10 blocks) were applied in
the recruitment of participants.
Each enrolled participant was provided a personal log-in to an on-
line, web-based system for which they were instructed to use during
the trial period. When agreeing to participate, the study investigator
typed in contemporary warfarin dose (last 14 days of warfarin tablets),
and two most recent INR measurements. This was done to instantiate
the model's ability to produce feasible predictions of INR values and
subsequently warfarin dose [13,16].
When logging in to the web-based system, participants were given
two options: 1) display the most recent dosage suggestion; 2) add
new data into the system.When selecting the latter option, participants
were required to type in the number of consumed tablets of warfarin
each day since the last data registration. Additionally, they could choose
to type in an INR valuemeasured in the timespan from last login and the
current day. Next, participants were presented a suggestion of the next
week's number ofwarfarin tablets; this suggestion could be approvedor
altered. If a participant was allocated to intervention, he/she would re-
ceive an algorithm-calculated dosage suggestion. In contrast, the dosage
suggestion in the placebo-armwould equal lastweek's dose ofwarfarin.
The trial arm allocationwas blinded for the participants, but recorded in
the database holding trial data. After confirmation of ‘planned’warfarin
dose, a detailed scheme of tablets per day was displayed to the partici-
pant. Next time the participants typed data into the system, they were
asked to confirm the actual number of tablets taken (each day) since
last login. If this numberwas different from the registered plannedwar-
farin dose, a ‘non-compliant’ registrationwasmade in the database. Par-
ticipants were instructed to use the system approximately once a week
(routine care), but no requirement on frequency of use was applied.
Three months after the initial trial-arm allocation, the web-based sys-
tem would automatically switch the participant to the other trial arm.
No follow-up visits weremade, but participants were encouraged to
contact the clinic if they had any doubts or questions concerning the
trail procedures, theweb-based system, or the treatment in general. Ad-
ditionally, a safety mechanism was built into the system on the inter-
vention arm: if a calculated dosage suggestion would exceed a
threshold of 20% difference relative to last week's dosage, the partici-
pant would not be presented this suggestion. Instead, the system
would display amessage instructing the participant to contact the clinic
by telephone. The study investigator would tell the dosage suggestion,
and in agreement with the participant, a ‘planned’ warfarin dosage
would be typed into the system by the study investigator.
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The algorithm is based on amodel, which is designed to handle time
series of daily warfarin intakes and INR values measured at designated
time points [16]. Based on these inputs the model is able to suggest a
warfarin maintenance dose to achieve target INR value. Model parame-
ters are initially set to population values and gradually, as data is en-
tered into the model, these parameters become patient specific.
The primary study endpoint, TTR, was calculated according to the
Rosendaal method [19]. Hereby the frequency of the INRmeasurements
and the actual values are incorporated assuming that changes between
consecutive INR measurements are linear over time. As a measure of
INR variabilitywe used log of the variance growth rate (logVGR) defined
by Fihn et al. [17] This quantifies the variability between patient's INR
values taking into account the time between INR measurements
A sample size calculation was done with a power of 0.8 to detect a
TTR difference of 5% between the control and intervention in an un-
paired comparison. The standard deviation (SD) in TTR was based on
Nielsen et al. [13] A sample size calculation corresponding to paired
comparisons was impossible due to the lack of an estimate of the SD
of change in TTR between dosing algorithms and standard care. We ex-
pected a drop-out rate of 5% in this trial.
Paired comparisons of TTR and INR variability between treatments
were done by paired t-tests. To accommodate for potential non-
normality confidence intervals were calculated by means of bootstrap.
The comparisons were repeated when stratified on INR target, random-
ization order andwarfarin dose groups. Non-compliance, i.e. substantial
difference between suggested and administered warfarin intake was
specified to imply additional analyses of (i) ‘reasons’ and (ii) ‘conse-
quences’ of a non-compliance registration.
All analyseswere performedwith the use of STATA software, version
13 (StataCorp LP, TX).
3. Results
A total of 211 patients were screened and deemed suitable for inclu-
sion, while 191 patients contributed to the main analysis and
randomised to either intervention or placebo. The main reasons for
dropout (n = 12) were lack of compliance to the web-based system
or patient preferences due to worsening of health-related conditions.
Initially, 113 patients were assigned to the intervention arm, while 86
patients were randomised to the placebo arm. A total of 191 patients
were crossed-over and completed at least 90 days of follow-up. The
mean follow-up time in the trial was 140 days.
Most of the patients were males (75%) and the mean age was
65 years, see Table 1. The majority of the patients had atrial fibrillation
(n = 103) as indication for warfarin treatment, while 39 patients hadTable 1
Patient characteristics.
Variable Number (%)
Number of participants 191
Mean age (SD) 65 (8.2)
Sex, male 144 (75%)
Indication for treatment
Atrial fibrillation 103 (54%)
Venous thromboembolism 39 (20%)
Heart valve replacement 41 (22%)
Other⁎ 8 (4%)
Years in VKA treatment (SD) 2 (1.6)
Target INR range
2.0 to 3.0 178 (93%)
2.5 to 3.5 13 (7%)
Average warfarin dose (IQR) 5.5 mg/day (5.0–7.5)
SD: Standard deviation. VKA: Vitamin K-antagonist. INR: International normalised
ratio. IQR: Interquartile range.
⁎ Sinus thrombosis; myocardial infarction/aneurism; stroke; polycythaemia.venous thromboembolism as primary indication. The average dose of
warfarin (based on an average of 14 days steady-state warfarin intake
before study start) was 5.5 mg/day.
3.1. Primary study outcomes
The TTR was overall comparable in the two trial arms during the
study period, see Table 2. The intervention arm achieved a TTR of 81.6,
while the placebo arm attained a TTR of 80.9 (difference [intervention
arm minus placebo arm]: 0.67 (95% confidence interval [CI] −2.93 to
4.27). The number of INR measurements were 11 (approximately
once every 8 days) in each randomisation allocation and was similar
in the two arms, i.e. a difference of 0.03 (−0.49 to 0.54);while the num-
ber of days contributed in the study period was markedly higher in the
intervention group: 19.57 (15.90 to 23.24), mainly due to the block
randomisation design. The logVGR was different in the two study
arms: 0.30 (0.14 to 0.47), favouring the placebo arm in terms of lower
logVGR according the method of Fihn's.
The primary result of comparable TTR in the two trial arms was ob-
served across all stratified analyses including warfarin dosing regimen
(low; middle; high), INR target range, and initial randomisation alloca-
tion [Table 2]. The intervention arm achieved a higher TTR in the high
dosing regimen compared to the low dosing regimen, 84.4 and 74.9, re-
spectively. We found no difference in TTR according to initial
randomisation allocation, which indicated that a learning bias was not
present in this study.
3.2. Additional analysis
The number of ‘non-compliant’ registrations (disagreement with
dosage suggestion) was different in the two trial arms, average 15%
per participant in the intervention arm and 6% in the placebo arm. As
described previously, this triggered additional analyses to investigate
the reason for non-compliance as well as the consequence (i.e. effect
on following INR measurement). Non-compliance was specifically cal-
culated as a difference between suggested and taken dose of warfarin
higher than 15% of the suggested dose. Hereby we deemed discrepan-
cies b0.8 mg/day (in average) to be compliant. Of note, in this analysis
we excluded patients who underwent bridging (n = 5), or patients
who preferred a different therapeutic target (n = 3) than the primary
indication (e.g. an atrial fibrillation patient preferred a target range of
2.5 to 3.5 rather than 2.0 to 3.0).
In Table 3 we focused on the period prior to an INR measurement
leading to potential non-compliance – i.e. the ‘reason’ for a non-
compliant registration. The three panels cross tabulates the frequency
of non-compliance based on the previous-to-current INR value (trend
or thedirection of change)minus the target INRvalue and the suggested
changes in weekly dose categorized as 1) taken dose N recommended
dose; 2) no dose discrepancy; and 3) taken dose b recommended dose. In
95.6% of the cases when the INR values were within target range, no
dose discrepancy was observed in the placebo arm. When the INR
values had a trend moving below target range, 11.4% of the cases the
dose taken was higher than the recommended dose. The dose was left
unchanged in the majority of these cases (88.6%), which reflects some
conservatism towards dosage changes in the participants. For the inter-
vention arm a somewhat similar pattern was observed. However, when
a trend of increasing INR values was observed (1 or more above INR
range), the taken warfarin dose was higher than the algorithm-
suggested dose in 22.4% of the cases. Correspondingly, in 27.8% of the
cases, when the trend of changes was towards 0.5 below INR target
range, the taken dose was below the algorithm-suggested warfarin
dose.
Table 4 shows the ‘consequence’ on the following INR value relative
to the chosen dose compliance or non-compliance. The INR values are
grouped in five levels as being in therapeutic range, being 0.5 above or
below, and N1 above and below. For the placebo arm, there was no
Table 2
Study outcomes according to trial study arms.
Control Intervention Difference, 95% CI
Days in follow-up 60.7 (26.6) 80.3 (16.4) 19.57 (15.90 to 23.24)
Number of INR measurements 11.3 (2.8) 11.3 (3.0) 0.03 (−0.49 to 0.54)
TTR (SD) 80.9 (24.0) 81.6 (18.5) 0.67 (−2.93 to 4.27)
logVGR −3.7 (1.2) −3.4 (0.9) 0.30 (0.14 to 0.47)
Warfarin dosing regimen
Low (n = 42) TTR 82.3 (22.3) 74.9 (23.8) −7.5 (−16.12 to 1.23)
logVGR −3.7 (1.1) −3.2 (0.9) 0.53 (0.20 to 0.86)
Middle (n = 111) TTR 80.0 (25.0) 83.1 (17.2) 3.18 (−1.42 to 7.77)
logVGR −3.7 (1.3) −3.5 (0.9) 0.20 (−0.03 to 0.43)
High (n = 38) TTR 82.1 (23.2) 84.4 (13.4) 2.31 (−5.29 to 9.91)
logVGR −3.5 (1.3) −3.1 (0.9) 0.34 (−0.10 to 0.79)
INR target range
2.0–3.0 (n = 178) TTR 80.5 (24.3) 81.7 (18.4) 1.22 (−2.52 to 4.97)
logVGR −3.5 (1.0) −3.4 (0.9) 0.13 (−0.01 to 0.28)
2.5–3.5 (n = 13) TTR 87.2 (18.0) 80.3 (20.7) −6.92 (−20.21 to 7.04)
logVGR −3.5 (1.0) −3.0 (1.0) 0.46 (−0.12 to 1.04)
Initial randomisation allocation
Control first (n = 84) TTR 80.5 (26.3) 80.4 (17.6) −0.10 (−6.30 to 6.09)
logVGR −3.6 (1.3) −3.3 (0.8) 0.35 (0.04 to 0.67)
Intervention first (n = 107) TTR 81.2 (22.0) 82.5 (19.1) 1.27 (−3.02 to 5.56)
logVGR −3.7 (1.1) −3.4 (1.0) 0.26 (0.01 to 0.52)
INR: International normalised ratio. TTR: Time in therapeutic range. SD: Standard deviation. VGR: Variance growth rate. CI: Confidence interval.
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the effect of the following INR value. A similar non-consistency between
dose selection and consequence on INR valuewas observed in the inter-
vention arm.
In general, as displayed from the results presented in Tables 3 and 4,
we were not able to identify a clear pattern of behaviour from the par-
ticipants according to neither reason nor the consequence in relation to
non-compliance of warfarin dosage suggestions.
4. Discussion
In this randomised controlled, cross-over designed trialwe observed
similar TTR in routine PSM care and in patients who received an addi-
tional warfarin dosage suggestion. The INR variability expressed as the
logVGR was slightly higher in the intervention group, indicating that
the serial INR values fluctuated more compared to that of the placebo
group. We also observed a higher degree of ‘non-compliance’ to dosage
suggestion in the intervention group, but no pattern of the reason for
this behaviour could be detected.
In general, the TTR in both groups was very high (N80%) indicating
excellent quality of the OAC treatment. The patients included for ran-
domization were all in steady-state warfarin treatment, and were edu-
cated in PSM of the treatment. In this education programme, theyTable 3
Cross-tabulated ‘reason’ for non-compliance to a warfarin dosage suggestion for the two
trial arms. Each cell indicates the frequency of compliance (no dose discrepancy) or
non-compliance according to changes from previous-to-current INR-deviation relative
to INR-target – i.e. the trend of change in INR values.
Taken N
recommended
No dose
discrepancy
Taken b
recommended
INR
measurements
Placebo arm
1 or more above 0% 70% 30% 54
0.5 above 2.0% 94.0% 4.0% 151
Within range 2.2% 95.6% 2.2% 1251
0.5 below 11.4% 88.6% 0% 70
1 or more below 60.0% 40.0% 0% 5
Intervention arm
1 or more above 22.4% 65.7% 11.9% 67
0.5 above 2.2% 91.2% 6.6% 226
Within range 2.5% 86.1% 11.4% 1637
0.5 below 9.2% 63.0% 27.8% 119
1 or more below 50.0% 50.0% 0% 6were instructed to be reluctant towards changes in dose despite INR
values being out of target range. The main reason for this was to avoid
an ‘oscillating’ effect, but instead await dose changes until a clear
trend in serial INR valueswas observed [20]. In the current study, the in-
cluded patients had good access to clinical sparring with trained care-
takers in OAC treatment. Specifically, they were instructed to make
telephone contact or use online communication (standard email or
message service in CoaguChek Link) if assistance in warfarin dosing
was required. We were not able to investigate if use of the algorithm-
based dosage suggestion improved the TTR compared to before com-
mencing the study.
Indeed, high quality of OAC treatment reflected by TTR is pivotal to
reduce the risk of bleeding and thromboembolic events [3]. We have
previously shown in retrospective investigations that the developed
model could potentially improve TTR [13]. However, due to the retro-
spective nature of these studies, it was not possible to ascertain if the
magnitude of these warfarin dose suggestions would be too high/low
and thus cause risks of serious adverse events. We therefore conducted
this trial in a selected cohort of well-trained OAC-PSM patients to min-
imize safety aspects, as the patients per se are reluctant to (large) dose
changes. Clearly, the proposed algorithm is not to be used in an excel-
lent quality setting in the future. However, as we obtained positive re-
sults in this prospective trial, it appears safe to investigate if the model
may perform similarly in a setting with lower OAC quality, e.g. in gener-
al practice. In routine OAC settings in general practice, the frequency of
INR measurement are often lower compared to PSM settings, and the
treating physician may have limited expertise in optimal dose adjust-
ments of warfarin to maintain stroke prophylaxis.
Use of coumarin dosage suggestion is being used in different settings
to either maintain INR target and/or to provide guidance in dosing to
obtain steady-state treatment. Computer aided dosing has been
shown tomake dosing easier andmore efficient in the Swedish national
quality registry, Auricula [21]. This system is based on N700 (hidden)
dosing rules. A commercially available system (DAWN AC) has been
tested in a multicentre setup and improved the TTR from 63.4% to
66.8% during the investigation period [15]. However, in a randomised
comparison between a simple decision rule for warfarin dosing vs the
DAWN AC, the maintenance control of INR was similar [22]. In general,
most investigations on use of computer aided coumarin dosing has been
shown to be safe and effective as well as cost-effective [14,23,24].
The quality of OAC treatment with vitamin K-antagonists is often
measured by TTR. However, it has been shown that TTR correlates
Table 4
Cross-tabulated ‘consequence’ of non-compliance to warfarin dosing suggestion for the two trial arms. Each cell indicates the frequency of compliance (no dose discrepancy) or non-com-
pliance to dose suggestion and the effect on the following INR measurement.
1 or more above 0.5 above Within range 0.5 below 1 or more below INR measurements
Placebo
Taken N recommended 0% 18.4% 68.4% 13.2% 0% 38
No dose discrepancy 2.5% 10.2% 82.9% 4.4% 0.4% 1378
Taken b recommended
Intervention
Taken N recommended 5.6% 8.5% 77.5% 7.0% 1.4% 71
No dose discrepancy 4.0% 11.3% 79.2% 5.4% 0.1% 1639
Taken b recommended 2.3% 7.1% 80.1% 8.5% 0.9% 224
5P.B. Nielsen et al. / Clinical Trials and Regulatory Science in Cardiology 25 (2017) 1–6poorly with clinical endpoints [25]. In the current study, we did not in-
vestigate if the algorithm dosing resulted in fewer clinical events. Nev-
ertheless, we acknowledge that TTR as a surrogate of OAC quality may
not directly translate into clinical value. Other groups have reported
that INR variability is also an importantmeasurewhen assessing quality
of OAC treatment. Razouki et al. investigated the addition of logVGR to
predict adverse events in 40,404 anticoagulated patients [26]. With an
overall TTR of 64% they observed a log INR variability of −3.41. They
concluded that INR variability adds important information on top of
TTR when predicting adverse events. The reported INR variability from
Razouki et al. is comparable to our results [Table 2], while we obtained
a markedly higher TTR. One explanation of the weak correlation be-
tween variability and TTR could be the frequency of measurements
and the different observation time between the two studies. Naturally,
we were not able to evaluate if the INR variability could have been
lower in our study, if the patients were required to comply with the
warfarin dosage suggestions.
Our study has some limitations that should be emphasized. The on-
line system used in the study was affected by periodically malfunction
during the first three initial weeks. The reason for the malfunction
was detected and corrected, and sensitivity analyses by excluding this
period was performed but did not affect our results [data not shown].
We imposed an intention-to-treat analysis on the main outcome.
Hence, we did not assess if the comparisons was affected by bridging
periods or patient's target preferences. The non-compliance option in
the study design caused us to be unable to determine if the algorithm
performs optimal in all dosage regimens and levels of INR values. As
seen from the additional analyses [Tables 3 and 4], we were therefore
not able to evaluate any reasons of non-compliance to dosage sugges-
tions. We only included long-term VKA treated, steady-state PSM pa-
tients in this study, which could impose a selection bias. As such, our
results of excellent OAC quality by use of the dosing algorithm could
be hypnotised not apply to other settings with lower (baseline) OAC
quality.
In conclusion, we found no difference between the two trial-arms in
a high quality OAC setup, however in general, the model performed
similarly as to routine PSM care. We could not assess if higher quality
of treatment was obtainable in patients were mandated to follow algo-
rithm dosing suggestions. Further studies are needed to assess if the
model is a feasible tool for patients managed in settings with expected
overall lower quality of OAC treatment with warfarin.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ctrsc.2016.11.002.Disclosures and funding
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